Szepanowski, Fabian
Warnke, Clemens
Meyer zu Hörste, Gerd
Mausberg, Anne K.
Hartung, Hans-Peter
Kleinschnitz, Christoph
Stettner, Mark
Funding for this research was provided by:
Octapharma provided a grant for writing the article. Octapharma did not have any influence on the contents for which the authors are entirely responsible.
Universitätsklinikum Essen
Article History
Accepted: 13 September 2021
First Online: 16 October 2021
Declarations
:
: Open Access funding enabled and organized by Projekt DEAL. Octapharma provided a grant for writing this review article. Octapharma did not have any influence on the contents, for which the authors are entirely responsible.
: F. Szepanowski has no conflicts of interest. C. Warnke has received institutional support from Novartis, Biogen, Alexion, Janssen, and Roche. G. Meyer zu Hörste served on scientific advisory boards for LFB and received speaker honoraria from Alexion. A. Mausberg has no conflicts of interest. H-P. Hartung received personal fees for consulting, serving on steering and data monitoring committees from Bayer Healthcare, Biogen, Celgene Receptos, CSL Behring, GeNeuro, MedImmune, Merck, Novartis, Octapharma, Roche, Sanofi Genzyme, Teva. C. Kleinschnitz has received remuneration for lectures and advisory boards from Alexion, Almirall, Amgen, Amicus, Bayer, Biogen, Biotronik, Boehringer Ingelheim, Bristol Myers-Squibb, Celgene, CSL Behring, Daiichi Sankyo, Desitin, Eisai, Ever Pharma, GE Healthcare, MedDay Pharmaceuticals, Merck Serono, Mylan/Viatris, Novartis, Pfizer, Roche, Sanofi-Genzyme, Siemens, STADA, Stago, Teva. C. Kleinschnitz owns shares: Sanofi < 30.000 €. Biontec < 30.000 €. M. Stettner served on the scientific advisory boards and/or received speaker honoraria, travel funding or honoraria for medical writing from UCB, Biogen Idec, Grifols, Genzyme, Roche, Merck, Novartis, Octapharma, CSL Behring, Sanofi-Aventis, TEVA, and Bayer.
: Not applicable
: Not applicable
: Not applicable
: Not applicable
: Not applicable
: All authors take responsibility for the integrity and accuracy of data interpretation and statements. Review concept and design: MS, FS. Drafting of the manuscript: MS, FS. Critical revision of the manuscript for intellectual content: MS, CW, GMH, H-PH, CK. All authors have read and approved the final version of the manuscript.